A Tax on Being Thin: Only High Earners Make Overall Savings on Food Bills from Weight-Loss Drugs

A recent analysis by consultancy Baringa has revealed that only high earners will reap any savings from taking expensive weight-loss medication, such as GLP-1s. These medications cost £1,200 per year and are intended to help people lose weight without sacrificing a penny on food bills.

However, for most people, the cost of these medications far outweighs any potential benefits. The regressive tax that comes with being thin is a stark reminder of the inequality that pervades our healthcare system. With 14.3 million adults living with obesity in England, one would expect weight-loss medication to be a lifeline for those struggling with their weight.

According to PwC research, only 6% of GLP-1 users come from households earning less than £20,000, while 20% are from the wealthiest households earning above £100,000. This is not just a matter of affordability; it’s also about accessibility. The NHS commissioning process is supposed to protect against financial inequity, but access to GLP-1s on the NHS is limited only to a small eligible cohort.

Independent Pharmacies Association chair Dr Leyla Hannbeck notes that many people who might benefit from these medications are unable to access treatment at all unless they can afford private care. The industry’s response to this problem has been underwhelming, with companies prioritizing profit over addressing underlying issues.

The consequences of this are stark. For patients who cannot afford to continue taking these medications, the pattern is all too familiar: they start losing weight, then stop treatment due to cost pressures, and eventually regain their original weight. This cycle perpetuates inequality and reinforces the notion that weight-loss is a short-term quick fix rather than a sustained lifestyle change.

As we continue down this path, it’s worth asking what this means for our healthcare system as a whole. Will we see a new generation of fat taxes, where being thin becomes a privilege reserved for the wealthy? Or will we finally recognize the need to address the underlying causes of obesity and provide accessible, affordable care for all?

The answer lies in how we choose to frame the conversation around weight-loss medication. Do we view it as a luxury item, only available to those who can afford it, or do we see it as a fundamental right that should be protected from regressive taxes? The choice is ours – and it’s time to make the right one.

The weight of exclusion may seem like a small price to pay for a slimmer waistline, but in reality, it’s a heavy burden that only serves to perpetuate inequality. It’s time to rethink our approach to weight-loss medication and ensure that everyone has access to the care they need – regardless of their income or social status.